Cerulean’s clinically validated nanoparticle drug conjugates (NDCs) platform allows us to:

  • Develop our own small molecule oncology products
  • Potentially solve class limiting problems such as delivery of siRNA
  • Develop products with partners by marrying their molecules, marketed or in development, with our platform

Learn more about CRLX101

Learn more about CRLX301

Learn more about Cerulean’s RNA Delivery Program